-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1908 Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Diseases, Lymphoid Malignancies, emerging technologies, Technology and Procedures, Minimal Residual Disease , Serologic Tests
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Michael J Slade, MD, MS1, Abir Khalid, PhD2*, Mark A Fiala, PhD3*, Mariya Liyasova, PhD4*, Mark A Zaydman, MD, PhD5*, Zac McDonald, PhD4*, Julie M Fortier, PhD3*, Sarah Kelley6*, Zachary D. Crees, MD7, Mark A. Schroeder, MD8, Keith E Stockerl-Goldstein, MD3, Liqiang Yang, PhD4* and Ravi Vij, MD, MBBS8

1Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
2Rapid Novor, Kitchener, ON, Canada
3Department of Medicine, Division of Hematology & Oncology, Washington University School of Medicine, St. Louis, MO
4Rapid Novor Inc, Kitchener, ON, Canada
5Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, Saint Louis, MO
6Washington University School of Medicine, St. Louis, MO
7Division of Oncology, Washington University School of Medicine, St. Louis, MO
8Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO

The presence of measurable residual disease (MRD) is an important prognostic factor for multiple myeloma. However, MRD tests in current clinical use require bone marrow (BM) samples that are uncomfortable, expensive, and time-consuming for patients. BM-based assays are also limited by sampling of a single location within the marrow, which may not accurately represent overall disease burden. Consequently, there is an urgent unmet need for peripheral blood-based MRD testing that would allow for convenient, repeated assessment of MRD.

M-protein quantification using mass spectrometry (MS) is promising candidate methodology for peripheral blood MRD monitoring due to its exceptional analytical sensitivity. Specifically, “clonotypic” MS techniques can identify and track a specific M-protein “peptide fingerprint”, allowing sensitive and specific measurement of MRD that may exceed BM-based techniques. However, clinical data regarding this approach is limited and no clonotypic MS assays are currently in clinical practice.

Consequently, we performed a pilot study to assess the use of clonotypic MS-based MRD testing using the EasyM system (Rapid Novor, Kitchener, ON). We retrospectively identified a subset of patients in our institutional tissue bank who met the following criteria: 1) IgG multiple myeloma, 2) M-protein ≥0.5 g/dL by serum protein electrophoresis (SPEP) at diagnosis, and 3) adequate samples for analysis. Baseline and follow up serum samples were analyzed by the study sponsor in a blinded fashion. EasyM results were subsequently compared to SPEP and, when available, next generation sequencing MRD testing with the clonoSeq assay (Adaptive, Seattle, WA). We used receiver-operator curve analysis to identify cutoffs for percent reduction in EasyM to predict BM-based MRD using the R package “cutpointr”.

19 patients were identified for analysis. Median age was 62 and 52% were male. All patients received proteasome inhibitor-based induction and 17 patients received lenalidomide. All underwent autologous stem cell transplant (ASCT) in first remission. A clonotypic signature was identified in all 19 patients from the baseline sample. 54 follow up samples were analyzed. Percent change in EasyM and SPEP were well correlated (Pearson R = 0.808; p < 0.01). 37 timepoints had MRD testing available. Of these, 14 and 9 timepoints were negative at 10-5 and 10-6, respectively; only 3 (8%) had undetectable M-protein by EasyM, all MRD negative at 10-6.

Using receiver-operator curve analysis, we identified optimal cutoffs for percent reduction in EasyM by area under the curve for BM-based MRD at 10-5 (99.0%) and 10-6 (99.3%) thresholds. The PPV and NPV for EasyM at 10-5 were 91% and 80%. The PPV and NPV for EasyM at 10-6 were 92% and 58%. Given the half-life of IgG (2 – 3 weeks), we also performed an exploratory analysis for MRD at 10-5 separating day 100 samples (n = 18) from later samples (n = 18). This analysis yielded slightly different optimal cutoffs for percent reduction by EasyM for day 100 (98.2%) versus later timepoints (99.4%), with similar PPV (91% and 92%) and improved NPV (100% for both), suggesting time of sample collection may impact the predictive value of EasyM.

At day 100 after ASCT, 7 patients were in CR, 9 in VGPR and 3 in PR. 7 patients progressed during the follow up period. One patient had undetectable EasyM at day 100 after ASCT and received only 4 months of post-ASCT lenalidomide, but remains in CR over 3 years after transplant. Two patients achieved undetectable EasyM at 9 and 55 months, respectively, post-ASCT and remain in CR at 52 and 64 months.

Our study provides initial data regarding clonotypic MS with the EasyM assay for peripheral blood MRD testing. We demonstrated excellent correlation between percent reduction in M-protein by SPEP and EasyM. Interestingly, 79% of samples that were MRD negative at 10-5 by clonoSeq had detectable M-protein by clonotypic MS, suggesting EasyM may be a more sensitive test for residual disease. After optimization, EasyM showed excellent PPV and NPV for BM-based MRD negativity, suggesting clonotypic MS be able to identify patients who can forego a bone marrow biopsy for MRD monitoring. We are currently validating this assay in non-IgG isotypes and light chain disease. Overall, clonotypic MS represents a promising new tool for myeloma monitoring and should be performed in larger retrospective cohorts and integrated into prospective trials for further validation.

Disclosures: Khalid: Rapid Novor: Current Employment. Liyasova: Rapid Novor: Current Employment. Zaydman: Siemens Healthineers: Honoraria. McDonald: Rapid Novor: Current Employment. Crees: BioLineRx Ltd.: Research Funding. Schroeder: Seagen Inc.: Research Funding; Fortis: Research Funding; Amgen: Research Funding; Cellect Inc: Research Funding; Genentech Inc: Research Funding; Incyte: Research Funding; Celgene: Research Funding. Yang: Rapid Novor: Current Employment. Vij: Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.

*signifies non-member of ASH